The manufacturer advises patients who are insulin and GLP-1 RA nave to start at 10 units daily, whereas those that are currently on basal insulin can start at 16 units daily
Additionally, 40.4% of individuals treated with CagriSema achieved a weight loss of 25% or greater after 68 weeks, in contrast to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and just 0.9% with placebo
Low (518%), due to saturable intestinal absorption
However, even small increases in GLP-1 levels achieved by enhanced secretion or slowed degradation can have significant effects on glucose homeostasis, appetite regulation, and gastrointestinal motility
The medication reaches steady-state levels within four to five weeks of weekly dosing, meaning your body maintains therapeutic concentrations regardless of the exact day or time you inject